ES2134294T3 - Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos. - Google Patents
Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos.Info
- Publication number
- ES2134294T3 ES2134294T3 ES94109426T ES94109426T ES2134294T3 ES 2134294 T3 ES2134294 T3 ES 2134294T3 ES 94109426 T ES94109426 T ES 94109426T ES 94109426 T ES94109426 T ES 94109426T ES 2134294 T3 ES2134294 T3 ES 2134294T3
- Authority
- ES
- Spain
- Prior art keywords
- diagnosis
- treatment
- oncogens
- expressive
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 230000003211 malignant effect Effects 0.000 title 1
- 230000009257 reactivity Effects 0.000 title 1
- 238000001514 detection method Methods 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Mycology (AREA)
Abstract
SE PRESENTAN METODOS PARA LA DETECCION, VIGILANCIA Y TRATAMIENTO DE MALIGNIDADES. LA DETECCION DE LA PROLIFERACION DE LAS CELULAS T EN RESPUESTA A LA EXPOSICION IN VITRO A UN PRODUCTO DE EXPRESION DE UNA PROTEINA DE UN ONCOGEN ACTIVADO O DE UN GEN RELACIONADO CON EL CANCER ASOCIADO CON UNA MALIGNIDAD, O LA DETECCION DE INMUNOCOMPLEJOS FORMADOS ENTRE EL PRODUCTO DE EXPRESION DE LA PROTEINA Y LOS ANTICUERPOS EN EL FLUIDOS CORPORAL, PERMITE LA DIAGNOSIS DE LA PRESENCIA DE UNA MALIGNIDAD. LA INVENCION TAMBIEN DESCUBRE METODOS Y COMPOSICIONES DE UNA MALIGNIDAD.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47064590A | 1990-01-26 | 1990-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2134294T3 true ES2134294T3 (es) | 1999-10-01 |
Family
ID=23868429
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94109426T Expired - Lifetime ES2134294T3 (es) | 1990-01-26 | 1991-01-24 | Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos. |
ES91903946T Expired - Lifetime ES2070492T3 (es) | 1990-01-26 | 1991-01-24 | Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91903946T Expired - Lifetime ES2070492T3 (es) | 1990-01-26 | 1991-01-24 | Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos. |
Country Status (10)
Country | Link |
---|---|
US (5) | US5320947A (es) |
EP (2) | EP0617124B1 (es) |
JP (3) | JP2552047B2 (es) |
AT (2) | ATE120860T1 (es) |
AU (1) | AU639311B2 (es) |
CA (1) | CA2074720C (es) |
DE (2) | DE69108716T2 (es) |
DK (1) | DK0617124T3 (es) |
ES (2) | ES2134294T3 (es) |
WO (1) | WO1991011719A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2011099A1 (en) * | 1989-04-19 | 1990-10-19 | Stephen C. Wardlaw | Determination of lymphocyte reactivity to specific antigens in blood |
EP0617124B1 (en) * | 1990-01-26 | 1999-05-19 | Washington Research Foundation | Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy |
GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
AU666336B2 (en) * | 1991-09-16 | 1996-02-08 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Detection method for C-RAF-1 genes |
US5512473A (en) * | 1993-01-29 | 1996-04-30 | Brent; Roger | Max-interacting proteins and related molecules and methods |
US6953573B1 (en) | 1993-03-17 | 2005-10-11 | University Of Washington | Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US6156316A (en) * | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
US6942862B2 (en) * | 1996-04-01 | 2005-09-13 | University Of Washington | Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins |
AU5587998A (en) | 1996-11-15 | 1998-06-03 | Cornell Research Foundation Inc. | Activated ras interaction assay |
DE19736691A1 (de) * | 1997-08-22 | 1999-02-25 | Michael Prof Dr Med Giesing | Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen |
US6551780B1 (en) * | 2000-03-31 | 2003-04-22 | The Regents Of University Of California | Detection of gene mutations or amplifications in melanocytic neoplasms |
US7060284B1 (en) * | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
CA2395136A1 (en) * | 1999-12-22 | 2001-06-28 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
US6772026B2 (en) * | 2000-04-05 | 2004-08-03 | Therics, Inc. | System and method for rapidly customizing design, manufacture and/or selection of biomedical devices |
US20030119079A1 (en) * | 2001-09-19 | 2003-06-26 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the breast |
US20040076978A1 (en) * | 2001-11-14 | 2004-04-22 | Catherine Verfaillie | Method to identify genes associated with chronic myelogenous leukemia |
EP1644473B1 (en) * | 2003-06-03 | 2014-01-15 | Cantimer Incorporated | Phase change sensor |
ES2586410T3 (es) | 2005-02-11 | 2016-10-14 | Memorial Sloan-Kettering Cancer Center | Procedimientos y composiciones de detección de un mutante de EGFR resistente a fármacos |
EP1912680B1 (en) * | 2005-06-15 | 2014-11-26 | The Ohio State University Research Foundation | Her-2 peptides |
US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
HUE039085T2 (hu) * | 2006-01-20 | 2018-12-28 | Cell Signaling Technology Inc | Transzlokáció és mutáns ROS kináz humán nem-kissejtes tüdõ karcinómában |
US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
EP1994181A4 (en) * | 2006-02-27 | 2010-05-19 | Univ Arizona | IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER |
US8171270B2 (en) * | 2006-12-29 | 2012-05-01 | Intel Corporation | Asynchronous control transfer |
US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
US11484581B2 (en) | 2017-06-02 | 2022-11-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Method to create personalized canine cancer vaccines |
WO2019055618A1 (en) | 2017-09-15 | 2019-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY |
WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4411990A (en) * | 1979-06-13 | 1983-10-25 | University Patents, Inc. | Primary bioassay of human tumor stem cells |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4643968A (en) * | 1981-01-29 | 1987-02-17 | Massachusetts Institute Of Technology | Process for determining metabolism and growth of cells under various conditions |
CA1219232A (en) * | 1983-08-17 | 1987-03-17 | Richard A. Lerner | Polypeptide-induced monoclonal receptors to protein ligands |
JPS62103573A (ja) * | 1985-08-21 | 1987-05-14 | オンコジ−ン・サイエンス・インコ−ポレ−テツド | Rasがコ−ドしているタンパク質の検出用イムノアツセイ |
JPH076982B2 (ja) * | 1985-11-06 | 1995-01-30 | 株式会社ニチレイ | 抗 体 |
AU596670B2 (en) * | 1986-05-06 | 1990-05-10 | Amgen, Inc. | Assays and antibodies for n-myc proteins |
US4820631A (en) * | 1986-07-30 | 1989-04-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Deletion mutants and monoclonal antibodies against ras proteins |
US4861589A (en) * | 1987-03-23 | 1989-08-29 | Trustees Of Boston University | Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells |
US4957859A (en) * | 1988-02-16 | 1990-09-18 | Hoffmann-La Roche Inc. | Antibodies for transforming ras protein |
DE69031120T2 (de) * | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
EP0617124B1 (en) * | 1990-01-26 | 1999-05-19 | Washington Research Foundation | Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy |
-
1991
- 1991-01-24 EP EP94109426A patent/EP0617124B1/en not_active Expired - Lifetime
- 1991-01-24 JP JP3504130A patent/JP2552047B2/ja not_active Expired - Fee Related
- 1991-01-24 AT AT91903946T patent/ATE120860T1/de not_active IP Right Cessation
- 1991-01-24 AU AU73299/91A patent/AU639311B2/en not_active Ceased
- 1991-01-24 ES ES94109426T patent/ES2134294T3/es not_active Expired - Lifetime
- 1991-01-24 DE DE69108716T patent/DE69108716T2/de not_active Expired - Fee Related
- 1991-01-24 ES ES91903946T patent/ES2070492T3/es not_active Expired - Lifetime
- 1991-01-24 AT AT94109426T patent/ATE180276T1/de not_active IP Right Cessation
- 1991-01-24 DK DK94109426T patent/DK0617124T3/da active
- 1991-01-24 WO PCT/US1991/000497 patent/WO1991011719A1/en active IP Right Grant
- 1991-01-24 EP EP91903946A patent/EP0513161B1/en not_active Expired - Lifetime
- 1991-01-24 DE DE69131255T patent/DE69131255T2/de not_active Expired - Fee Related
- 1991-01-24 CA CA002074720A patent/CA2074720C/en not_active Expired - Fee Related
-
1992
- 1992-01-13 US US07/820,409 patent/US5320947A/en not_active Expired - Lifetime
-
1994
- 1994-05-31 US US08/251,590 patent/US5601989A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/469,081 patent/US5773230A/en not_active Expired - Fee Related
- 1995-06-07 US US08/473,762 patent/US20030083229A1/en not_active Abandoned
-
1996
- 1996-02-29 JP JP8043483A patent/JPH08275774A/ja active Pending
-
1998
- 1998-06-16 JP JP10168736A patent/JPH1169976A/ja active Pending
-
2003
- 2003-09-24 US US10/671,328 patent/US20040235070A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2552047B2 (ja) | 1996-11-06 |
DE69131255D1 (de) | 1999-06-24 |
DK0617124T3 (da) | 1999-12-06 |
AU7329991A (en) | 1991-08-21 |
DE69108716D1 (de) | 1995-05-11 |
AU639311B2 (en) | 1993-07-22 |
US20040235070A1 (en) | 2004-11-25 |
JPH1169976A (ja) | 1999-03-16 |
WO1991011719A1 (en) | 1991-08-08 |
US5601989A (en) | 1997-02-11 |
CA2074720A1 (en) | 1991-07-27 |
JPH08275774A (ja) | 1996-10-22 |
US5773230A (en) | 1998-06-30 |
ES2070492T3 (es) | 1995-06-01 |
EP0513161B1 (en) | 1995-04-05 |
ATE180276T1 (de) | 1999-06-15 |
EP0513161A1 (en) | 1992-11-19 |
ATE120860T1 (de) | 1995-04-15 |
US20030083229A1 (en) | 2003-05-01 |
EP0617124B1 (en) | 1999-05-19 |
JPH05503996A (ja) | 1993-06-24 |
EP0617124A1 (en) | 1994-09-28 |
DE69108716T2 (de) | 1995-08-17 |
DE69131255T2 (de) | 1999-12-16 |
CA2074720C (en) | 2002-07-23 |
US5320947A (en) | 1994-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2134294T3 (es) | Reactividad inmune para oncogenes expresados activos para la diagnosis y el tratamiento de tumores malignos. | |
IT8027029A0 (it) | Complessi platino-diamminici e formulazioni farmaceutiche per il trattamento del cancro che licontengono. | |
ES2148838T3 (es) | Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer. | |
ES444494A1 (es) | Procedimiento para la preparacion de antracicliononas opti- camente activas. | |
NO931635D0 (no) | Fremgangsmaate for fremstilling av kinazolin-derivater | |
ES2134797T3 (es) | Peptidos y fragmentos de peptidos terapeuticamente utiles. | |
FR2312259A1 (fr) | Medicament anti-tumoral | |
FI952607A (fi) | Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi | |
SE8000435L (sv) | N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning | |
TR199800270T1 (xx) | Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�. | |
IT7905216A0 (it) | Soluzione di amminoacidi per pazienti affetti da carcinoma. | |
FR2657259B1 (es) | ||
SE402213B (sv) | Konstgjord stoma for perkutan genomforing av i kroppen inopererade, langstreckta implantat | |
RU94034104A (ru) | Способ увеличения цитотоксичности химиотерапевтического агента, набор для лечения и средство для производства лекарств | |
GB1446536A (en) | Pharmaceutically active compositions | |
CH554669A (de) | Operationstische fuer medizinische zwecke. | |
RU93042874A (ru) | Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии | |
BR9609620A (pt) | 2-aminocarbonil-1,2-bis(metilsulfonil)-1-(substituìda s)hidrazinas antitumorais. | |
HUP0204216A2 (en) | A new use of antibodies as vaccines | |
ATE246929T1 (de) | Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen | |
ES2137172T3 (es) | Vacunas antitumorales que comprenden celulas transfectadas con il-6. | |
FI810380L (fi) | Fenylpiperazinderivat av 1,3,4-oxadiazolylfenoler deras framstaellning och dessa innehaollande terapeutiska aemnen | |
ES2164011B1 (es) | Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos. | |
NO20030420L (no) | Medikament for immunoterapi av maligne tumorer | |
SE7603223L (sv) | 13,14-dehydro-11-deoxi-prostaglandiner och forfarande for deras framstellning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 617124 Country of ref document: ES |